Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Evens

Showing results (221-230 of 253) with videos related to

Pageof 26
Sort By:
Leukemia & Lymphoma|April 8, 2025
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failureEmily Anderson, Yun Choi, Rachel J Buchsbaum, et al.
Blood|August 16, 2005
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) ProjectCharles L Bennett, Denis Cournoyer, Kenneth R Carson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826Sharon M Castellino, Hongli Li, Alex F Herrera, et al.
Blood Advances|August 27, 2021
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphomaVictor M Orellana-Noia, Krista Isaac, Mary-Kate Malecek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
Blood Advances|January 4, 2018
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HLMonika Pilichowska, Stefania Pittaluga, Judith A Ferry, et al.
Cancer|September 14, 2017
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysisTara O Henderson, Susan K Parsons, Kristen E Wroblewski, et al.
Blood|March 7, 2009
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectKenneth R Carson, Andrew M Evens, Elizabeth A Richey, et al.
Cancer|July 28, 2017
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapyNarendranath Epperla, Kami J Maddocks, Mohammed Salhab, et al.
American Journal of Hematology|November 24, 2016
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapiesLuciano J Costa, Kami Maddocks, Narendranath Epperla, et al.
Pageof 26

Showing results (221-230 of 253) with videos related to

Sort By:
Pageof 26
Leukemia & Lymphoma|April 8, 2025
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failureEmily Anderson, Yun Choi, Rachel J Buchsbaum, et al.
Blood|August 16, 2005
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) ProjectCharles L Bennett, Denis Cournoyer, Kenneth R Carson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826Sharon M Castellino, Hongli Li, Alex F Herrera, et al.
Blood Advances|August 27, 2021
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphomaVictor M Orellana-Noia, Krista Isaac, Mary-Kate Malecek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
Blood Advances|January 4, 2018
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HLMonika Pilichowska, Stefania Pittaluga, Judith A Ferry, et al.
Cancer|September 14, 2017
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysisTara O Henderson, Susan K Parsons, Kristen E Wroblewski, et al.
Blood|March 7, 2009
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectKenneth R Carson, Andrew M Evens, Elizabeth A Richey, et al.
Cancer|July 28, 2017
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapyNarendranath Epperla, Kami J Maddocks, Mohammed Salhab, et al.
American Journal of Hematology|November 24, 2016
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapiesLuciano J Costa, Kami Maddocks, Narendranath Epperla, et al.
Pageof 26